iBio’s IBIO-610 Cuts 6.7% Visceral, 5.2% Total Fat Mass and Shows 33-Day Half-Life
iBio’s IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in obese non-human primates after two once-every-eight-week doses, while lean mass slightly increased. The antibody showed a 33.2-day half-life in primates with a projected human half-life of up to 100 days, supporting twice-yearly dosing.
1. Preclinical Efficacy in Primates
In a small obese non-human primate study, two doses of IBIO-610 administered once every eight weeks yielded a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass despite a high-calorie diet. Treated animals also exhibited a slight increase in lean mass, reflecting a fat-selective profile consistent across species.
2. Extended Half-Life and Dosing Potential
IBIO-610 demonstrated an extended 33.2-day half-life in primates, with pharmacokinetic modeling projecting up to a 100-day half-life in humans. This profile supports the feasibility of a twice-yearly dosing regimen, potentially improving patient compliance and treatment convenience.
3. Next Steps and Analysis
iBio plans to complete analyses of metabolic, biomarker, and mechanistic endpoints and will present the full dataset at scientific conferences throughout 2026. These findings underpin further evaluation of IBIO-610 as a differentiated therapy for obesity, cardiometabolic, and cardiopulmonary diseases.